[1]
|
Caruso R, Pallone F, Fina D, Gioia V, Peluso I, Caprioli F, Stolfi C, Perfetti A, Spagnoli LG, Palmieri G, Macdonald TT, Monteleone G. 2006. Protease-activated receptor-2 activation in gastric cancer cells promotes epidermal growth factor receptor trans-activation and proliferation. The American Journal of Pathology, 169(1): 268-278.
|
[2]
|
Cunningham MR, McIntosh KA, Pediani JD, Robben J, Cooke AE, Nilsson M, Gould GW, Mundell S, Milligan G, Plevin R. 2012. Novel role for proteinase-activated receptor 2 (PAR2) in membrane trafficking of proteinase-activated receptor 4 (PAR4). Journal of Biological Chemistry, 287(20): 16656-16669.
|
[3]
|
Darmoul D, Gratio V, Devaud H, Laburthe M. 2004. Protease-activated receptor 2 in colon cancer: trypsin-induced MAPK phosphorylation and cell proliferation are mediated by epidermal growth factor receptor transactivation. Journal of Biological Chemistry, 279(20): 20927-20934.
|
[4]
|
Déry O, Corvera CU, Steinhoff M, Bunnett NW. 1998. Proteinase-activated receptors: novel mechanisms of signaling by serine proteases. The American Journal of Physiology, 274(6): C1429-C1452.
|
[5]
|
Fujimoto D, Hirono Y, Goi T, Katayama K, Hirose K, Yamaguchi A. 2006. Expression of protease activated receptor-2 (PAR-2) in gastric cancer. Journal of Surgical Oncology, 93(2): 139-144.
|
[6]
|
Gratio V, Walker F, Lehy T, Laburthe M, Darmoul D. 2009. Aberrant expression of proteinase-activated receptor 4 promotes colon cancer cell proliferation through a persistent signaling that involves Src and ErbB-2 kinase. International Journal of Cancer, 124(7): 1517-1525.
|
[7]
|
Han N, Jin K, He KF, Cao J, Teng LS. 2011. Protease-activated receptors in cancer: A systematic review. Oncology Letters, 2(4): 599-608.
|
[8]
|
Ikeda G, Isaji S, Chandra B, Watanabe M, Kawarada Y. 1999. Prognostic significance of biologic factors in squamous cell carcinoma of the esophagus. Cancer, 86(8): 1396-1405.
|
[9]
|
Jiang P, Yu GY, Zhang Y, Xiang Y, Hua HR, Bian L, Wang CY, Lee WH, Zhang Y. 2013. Down-regulation of protease-activated receptor 4 in lung adenocarcinoma is associated with a more aggressive phenotype. Asian Pacific Journal of Cancer Prevention, 14(6): 3793-3798.
|
[10]
|
Kaufmann R, Rahn S, Pollrich K, Hertel J, Dittmar Y, Hommann M, Henklein P, Biskup C, Westermann M, Hollenberg MD, Settmacher U. 2007. Thrombin-mediated hepatocellular carcinoma cell migration: cooperative action via proteinase-activated receptors 1 and 4. Journal of Cellular Physiology, 211(3): 699-707.
|
[11]
|
Kawabata A, Kuroda R, Nishikawa H, Kawai K. 1999. Modulation by protease-activated receptors of the rat duodenal motility in vitro: possible mechanisms underlying the evoked contraction and relaxation. British Journal of Pharmacology, 128(4): 865-872.
|
[12]
|
Knecht W, Cottrell GS, Amadesi S, Mohlin J, Skåregärde A, Gedda K, Peterson A, Chapman K, Hollenberg MD, Vergnolle N, Bunnett NW. 2007. Trypsin IV or mesotrypsin and p23 cleave protease-activated receptors 1 and 2 to induce inflammation and hyperalgesia. Journal of Biological Chemistry, 282(36): 26089-26100.
|
[13]
|
Lan RS, Stewart GA, Henry PJ. 2000. Modulation of airway smooth muscle tone by protease activated receptor-1, -2, -3 and -4 in trachea isolated from influenza A virus-infected mice. British Journal of Pharmacology, 129(1): 63-70.
|
[14]
|
Ma L, Perini R, McKnight W, Dicay M, Klein A, Hollenberg MD, Wallace JL. 2005. Proteinase-activated receptors 1 and 4 counter-regulate endostatin and VEGF release from human platelets. Proceedings of the National Academy of Sciences of the United States of America, 102(1): 216-220.
|
[15]
|
Macfarlane SR, Seatter MJ, Kanke T, Hunter GD, Plevin R. 2001. Proteinase-activated receptors. Pharmacological Reviews, 53(2): 245-282.
|
[16]
|
Matej R, Mandáková P, Netíková I, Poucková P, Olejár T. 2007. Proteinase-activated receptor-2 expression in breast cancer and the role of trypsin on growth and metabolism of breast cancer cell line MDA MB-231. Physiological Research, 56(4): 475-484.
|
[17]
|
Ribeiro FS, Simãão TA, Amoêdo ND, Andreollo NA, Lopes LR, Acatauassu R, Rumjanek FD, Albano RM, Pinto LF, Monteiro RQ. 2009. Evidence for increased expression of tissue factor and protease-activated receptor-1 in human esophageal cancer. Oncology Reports, 21(6): 1599-1604.
|
[18]
|
Uusitalo-Jarvinen H, Kurokawa T, Mueller BM, Andrade-Gordon P, Friedlander M, Ruf W. 2007. Role of protease activated receptor 1 and 2 signaling in hypoxia-induced angiogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology, 27(6): 1456-1462.
|
[19]
|
Wang X, Liu HT, Li S, Li K, Lin N, Fan QX, Zheng YL. 2010. Prognostic value of protease-activated receptor 2 expression in oesophageal squamous cell carcinoma. The Journal of International Medical Research, 38(4): 1381-1388.
|
[20]
|
Xu WF, Andersen H, Whitmore TE, Presnell SR, Yee DP, Ching A, Gilbert T, Davie EW, Foster DC. 1998. Cloning and characterization of human protease-activated receptor 4. Proceedings of the National Academy of Sciences of the United States of America, 95(12): 6642-6646.
|
[21]
|
Yada K, Shibata K, Matsumoto T, Ohta M, Yokoyama S, Kitano S. 2005. Protease-activated receptor-2 regulates cell proliferation and enhances cyclooxygenase-2 mRNA expression in human pancreatic cancer cells. Journal of Surgical Oncology, 89(2): 79-85.
|
[22]
|
Zhang Y, Yu GY, Jiang P, Xiang Y, Li WL, Lee W, Zhang Y. 2011. Decreased expression of protease-activated receptor 4 in human gastric cancer. The International Journal of Biochemistry & Cell Biology, 43(9): 1277-1283.
|